Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 320

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients

Open access
Allegretti, Jessica R., Kassam, Zain, Mullish, Benjamin H., Chiang, Austin, Carrellas, Madeline, Hurtado, Jonathan, Marchesi, Julian R., McDonald, Julie A.K., Pechlivanis, Alexandros, Barker, Grace F., Miguéns Blanco, Jesús, Garcia-Perez, Isabel, Wong, Wing Fei, Gerardin, Ylaine, Silverstein, Michael, Kennedy, Kevin, Thompson, Christopher·2020·Clinical Gastroenterology and Hepatology

Abstract

BACKGROUND & AIMS Studies in mice have shown that the intestinal microbiota can contribute to obesity via the anorexigenic gut hormone glucagon-like peptide 1 (GLP1) and bile acids, which affect lipid metabolism. We performed a randomized, placebo-controlled pilot study of the effects of fecal microbiota transplantation (FMT) in obese, metabolically uncompromised patients. METHODS We performed a double-blind study of 22 obese patients (body mass index [BMI] ≥ 35kg/m2) without a diagnosis of diabetes, non-alcoholic steatohepatitis, or metabolic syndrome. Participants were randomly assigned (1:1) to groups that received FMT by capsules (induction dose of 30 capsules at week 4 and maintenance dose of 12 capsules at week 8) or placebo capsules. FMT capsules were derived from a single, lean donor (BMI, 17.5 kg/m2). Patients were followed through week 26; the primary outcome was safety. Stool and serum samples were collected from patients at baseline and at weeks 1, 4, 6, 8 and 12 after administration of the first dose of FMT or placebo and analyzed by 16S RNA gene sequencing. Stool and serum samples were analyzed for metabolomics by liquid chromatography-mass spectrometry. Additional outcomes were change in area under the curve for GLP1 at week 12. RESULTS We observed no significant differences in adverse events between patients who received FMT vs placebo. There was no increase in the area under the curve of GLP1 in either group. Patients who received FMT had sustained shifts in microbiomes associated with obesity toward those of the donor (P<.001). Patients who received FMT had a sustained decrease in stool levels of taurocholic acid (P<.05), compared with baseline; bile acid profiles began to more closely resemble those of the donor. We did not observe significant changes in mean BMI at week 12 in either group. CONCLUSIONS In a placebo-controlled pilot study, we found that FMT capsules (derived from a lean donor) were safe but did not reduce BMI in obese metabolically uncompromised patients. The FMT capsules were well tolerated and led to sustained changes in the intestinal microbiome and bile acid profiles that were similar to those of the lean donor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2019.07.006

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 320

Metadata

Authors
Allegretti, J. R., Kassam, Z., Mullish, B. H., Chiang, A., Carrellas, M., Hurtado, J., Marchesi, J. R., McDonald, J. A. K., Pechlivanis, A., Barker, G. F., Miguéns Blanco, J., Garcia-Perez, I., Wong, W. F., Gerardin, Y., Silverstein, M., Kennedy, K., & Thompson, C.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2020-04
Volume
18
Issue
4
Pages
855-863.e2
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2957227170
Cited by
320
References
27
FWCI
9.67
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Funders
  • Medical Research Council (MR/R000875/1)
  • Imperial College London
  • National Institute for Health Research
  • Imperial Biomedical Research Centre
  • Imperial College Healthcare National Health Service Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. https://app.cochat.ai/papers/10.1016/j.cgh.2019.07.006
The paper
Allegretti, J. R., Kassam, Z., Mullish, B. H., Chiang, A., Carrellas, M., Hurtado, J., Marchesi, J. R., McDonald, J. A. K., Pechlivanis, A., Barker, G. F., Miguéns Blanco, J., Garcia-Perez, I., Wong, W. F., Gerardin, Y., Silverstein, M., Kennedy, K., & Thompson, C. (2020). Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.07.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.